History 1 페이지 > Hwail Pharmaceutical

Korean  
Korean English
KOR l ENG
About Us
History

  • 2020

  • 09
    Inaugurated Cho, Joong-myung and Cho, Kyung-sook as CEO, respectively

  • 2018

  • 12
    Co-founded Supexbnp Co., Ltd. and Ascend Bio Co., Ltd. (50% stake)

  • 2016

  • 09
    Financed Investment Partnership in Posco Plutus Project 2 Fund
    03
    Revenue over $100 billion

  • 2015

  • 12
    Joint Acquisition of BTO Life Sciences (44.45% stake)
    08
    Acquired GMP Conformity Certificate of Hwaseong No. 4 Plant
    03
    Changed Co-CEOs to Cho, Jung-myung and Park, Pil-joon

  • 2013

  • 10
    Inaugurated  Cho Jung-myung, Lee Jung-gyu, and Park Pil-joon as Co-CEOs,
    Changed the Largest Stakeholder to Crystal Genomics Inc. 
    07
    Completion of Raw Material Synthesis No. 2 Plant Based on GMP (Hwaseong, Gyeonggi-do)
    01
    Registered Japanese Patent – Water-Soluble CoQ10

  • 2012

  • 02
    Appointed President of Korea Pharmaceutical Traders Association

  • 2011

  • 09
    09 Selected as the "Excellent Company with Human Respect Productivity" (Korea Productivity Center)
    08
    Change of Subsidiary Name from Hwail-Sepehr Diesel Kaveh international Co., Ltd to Hwail International Co., Ltd
    03
    Relocated Seoul office to Korea Bio Park in Pangyo
    01
    Selected as the Great Place to Work by Jobworld, Industrial Bank of Korea)

  • 2010

  • 12
    Signed Entecavir (hepatitis B) Synthetic Technology License Agreement with Hanmi Pharm. Co., Ltd.
    08
    Registered PCT Patent for Aqueous Nanoemulsion Composition Containing Conjugated Linoleic Acid
    03
    Foundation of a subsidiary of Hwail-Sepehr Diesel Kaveh international Co., Ltd,
    Issuance of Privately-placed Detachable Warrant Bonds with No-Guaranteed (Issue Amount: KRW 10 Billion)
    02
    Commendation from the Minister of Health, Welfare, and Family Affairs Due to Contribution to Enhancing People's Health and Welfare

  • 2009

  • 11
    Certificate of Merit for One Million Dollar Export Tower Award (Trade Day)
    Due to Contribution to Job Creation and Economic Development in Hwaseong-si (Regional Economics Association)

  • 2008

  • 12
    Strategic Partnership with Wafra-Phama, State-Owned Sudanese Pharmaceutical Company
    07
    Acquired Coenzyme Q10's Nanoemulsion Composition Patent,
    Commendation of the Minister of Knowledge Economy (Pharmaceutical, Medical Sector targeting enterprise by Maeil Business Newspaper)
    04
    Completion of Nanoemulsion Food Factory

  • 2007

  • 10
    Established a New Factory Exclusive to Nanoemulsion Technology
    07
    Completed Development of Water-Soluble Coenzyme Q10
    01
    01 Approved by the Ministry of Food and Drug Safety for Individual recognition for coenzyme Q10 Ingredients,
    Commendation of the Minister of Commerce, Industry, and Energy C (the 6th Digital Innovation B/T Division Grand Prize, Hankook Ilbo)

  • 2006

  • 10
    Designated as the Excellent Company Recognized for Productivity Improvement by the Minister of Commerce, Industry and Energy
    Commendation of the Minister of Commerce, Industry, and Energy's (2006 National Productivity Awards Innovation Sector, KPC)
    08
    Invested in Pangyo Bio Center Construction Consortium
    07
    Contracted the Commercialization of Water-soluble Coenzyme Q10
    06
    HPS-9955 Vision Proclamation Ceremony (Hwail Profit System)
    01
    Developed Coenzyme Q10 Successfully

  • 2005

  • 12
    Oseltamivir Phosphate (Treatment for Avian Flu - Ingredients of Tamiflu)
    06
    Acquired Cephalosporin Antibiotics Factory (GSK)
    03
    Implemented Increase of Capital Stock without Consideration (100%), KRW 5,040 million in capital
    02
    Commendation from the Minister of Health and Welfare

  • 2004

  • 05
    Registered Patent of Levosulpiride manufacturing process and intermediate used therefor

  • 2003

  • 12
    Commendation from the Minister of Commerce, Industry, and Energy (Industrial Cooperation Award)
    10
    Commendation from the Ministry of SMEs and Startup (Proud SMEs)

  • 2002

  • 12
    Selected as an Outstanding Enterprise Technology Company (Korea Technology Finance Corporation)
    11
    Synthesized Erdosteine Successfully
    10
    Implemented Increase of Capital Stock without Consideration (110%), KRW 252 million in capital
    06
    Selected as a CLEAN business establishment (Korea Occupational Safety and Health Agency)
    04
    BGMP Approval
    KOSDAQ Flotation
    Capital Increase of KRW 360 million (KRW 12 million)
    03
    Synthesized Alibendol(Digestive Medicine Promoting Bile Flow) for the first
    02
    Registered as a Venture Company

  • 2001

  • 12
    Registered Patent for the 4-amino-5 hexenoic acid manufacturing technique
    11
    Designated as a Company with Special Military Service
    09
    Completion of BGMP Facility
    06
    Designated as the Promising SME (Gyeonggi-do) and the Qualified Company for excellent drug distribution management criteria (KGSP)
    05
    Commendation from the Minister of Commerce, Industry, and Energy Due to the Development of SMEs
    Commendation from the Gyeonggi Governor Due to Enhancement of Labor-Management harmony and productivity
목록